Adoption of Patient-Centric Strategies Drives Interest in Pharmaceutical Digital Marketing, According to a Soon to Be Released Report by Global Industry Analysts, Inc.

GIA announces the launch of a comprehensive primary research program studying the global market for “Pharmaceutical Digital Marketing and Social Media”. The soon to be released report identifies pharma companies’ adoption of a more patient-centric business model as a key market driving force.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Pharmaceutical Digital Marketing and Social Media: A Global Multi-Client Research Initiative

San Jose, CA (PRWEB) December 10, 2013

Follow us on LinkedIn – GIA invites senior industry executives, domain experts, technologists and market strategists to participate in a comprehensive global research initiative studying the “Pharmaceutical Digital Marketing and Social Media” markets. The study will examine key drivers and trends impacting the market such as growing awareness among pharma companies over the importance of customer engagement against a backdrop of an emerging era of participatory medicine; increase in the number of social media projects undertaken by pharma companies worldwide; growing use of social media in drug development and discovery in addition to drug marketing; rise in the number of human clinical trials and the role played by social media in improving clinical trial enrolments; emerging significance of digital health and digital health feedback systems.

Defined as the use of digital marketing tools such as websites, e-mail, apps, and social media for superior customer experience management, Pharmaceutical Digital Marketing and Social Media is currently a ballooning phenomenon in the pharmaceutical industry. With the internet becoming a key source for accessing health related information, digital health defined as the convergence of internet, genomics, and healthcare, is exerting pressure on pharma companies to remain relevant in healthcare. With social media already entwined into the very fiber of modern society, the value of nurturing social confidence in drugs and therapies among patients and caregivers can no longer be undermined. Also, information assimilated from social media conversations can provide critical insights that can shape the success of clinical development programs. Information shared by physicians can accelerate the drug development process and increase the possibility of developing new indications for existing drugs. The market is also expected to benefit from the growing importance of pharmacovigilance, as companies struggle to build public confidence by maximizing drug safety all through the product’s lifecycle. Social media engagement in this regard can provide valuable post drug approval, real life data in the form of both solicited and unsolicited opinions on drug safety from patients and physicians.

With over 5000 new drugs currently in clinical development, the task of recruiting patients into clinical trials is a huge challenge for clinical trial sponsors. Social media engagement in the pharmaceutical Industry can help create public awareness and improve recruitment outcomes. The coming years are expected to witness companies increasingly manage patient enrolment and retention strategies such as online patient communities, social networking sites including Facebook, MySpace, and Twitter, online bulletin boards, blogs, and e-forums, among others.

The growing focus on reducing healthcare costs is also expected to encourage adoption of social media among pharmaceutical companies, since creation of a platform for information exchange at the community level provides a cost-effective direct marketing opportunity. The study estimates Pharmaceutical Digital Marketing and Social Media to be a multi-million dollar market worldwide, while more precise market-size and growth projections will be made available during the 2nd stage of report preparation, and data analysis.

The research and analyses will be released shortly in the form of a comprehensive research report. The report by design, will attempt to provide exhaustive analysis, data, trends, market share, market size, statistics, forecasts and competitive intelligence. The report is modeled to offer precise and unbiased, actionable market insights including in-depth segmentation of market sub-sectors, demand estimates and projections and analysis of trends in each of the sectors, identification of leading players, and the competitive structure, among others.

Developed for Pharmaceutical Companies, Strategic Planners, Business Development Executives, Management Consultants, Investment Bankers, Consulting Firms, Marketing & Sales Executives, C-Level Decision Makers, Market Strategists and Technology Domain Experts, the report helps identify the biggest opportunities in this space and offers accurate latent demand forecasting that empowers quantitative decision making among existing market players and new entrants.

For more details about how you can participate, please click here.

About Global Industry Analysts, Inc.

Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.

Follow us on LinkedIn.

Global Industry Analysts, Inc.
Telephone: 408-528-9966
Fax: 408-528-9977
Email: press(at)StrategyR(dot)com
Web Site: http://www.StrategyR.com/


Contact

Attachments